TRPV4 activation by TGFβ2 enhances cellular contractility and drives ocular hypertension
eLife · 2025
DOI: 10.7554/elife.104894 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Christopher Nass Rudzitis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, Salt Lake City, United States. Hauptthemen laut MEDLINE: TRPV Cation Channels, Transforming Growth Factor beta2, Ocular Hypertension, Trabecular Meshwork. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIH HHS, National Eye Institute.
Abstract (Originalsprache)
The risk for developing primary open-angle glaucoma (POAG) correlates with the magnitude of ocular hypertension (OHT) and the concentration of transforming growth factor-β2 (TGFβ2) in the aqueous humor. Effective treatment of POAG requires a detailed understanding of the interaction between pressure sensing mechanisms in the trabecular meshwork (TM) and biochemical risk factors. Here, we employed molecular, optical, electrophysiological, and tonometric strategies to establish the role of TGFβ2 in transcription and functional expression of mechanosensitive channel isoforms alongside studies of TM contractility in biomimetic hydrogels and intraocular pressure (IOP) regulation in a mouse model of TGFβ2-induced OHT. TGFβ2 upregulated expression of Trpv4 and Piezo1 transcripts and time-dependently augmented functional TRPV4 activation. TRPV4 agonists induced contractility of TM-seeded hydrogels, whereas pharmacological inhibition suppressed TGFβ2-induced hypercontractility and abrogated OHT in eyes overexpressing TGFβ2. Trpv4 -deficient mice resisted TGFβ2-driven increases in IOP, but nocturnal OHT was not additive to TGFβ-evoked OHT. Our study establishes the fundamental role of TGFβ as a modulator of mechanosensing in nonexcitable cells, identifies the TRPV4 channel as the final common mechanism for TM contractility and circadian and pathological OHT, and offers insights for future treatments that can lower IOP in the sizeable cohort of hypertensive glaucoma patients that resist current treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, Salt Lake City, United States.
- Department of Neurobiology, University of Utah, Salt Lake City, United States.
- Department of Ophthalmology and Visual Sciences, Syracuse, United States.
- Department of Cell and Developmental Biology, SUNY Upstate Medical University, Syracuse, United States.
- Department of Ophthalmology, Duke Eye Center, Duke University, Durham, United States.
- Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, United States.
ORCID-Profile: David Krizaj
Förderung
- NEI NIH HHS
- NIH HHS
- National Eye Institute
- Crandall Glaucoma Initiative
- Stauss-Ranking Foundation
- Research to Prevent Blindness
- National Institutes of Health
Zitieren
APA
Rudzitis, C. N., Lakk, M., Singh, A., Redmon, S. N., Kirdajová, D., Tseng, Y. T., De Ieso, M. L., Stamer, W. D., Herberg, S., & Krizaj, D. (2025). TRPV4 activation by TGFβ2 enhances cellular contractility and drives ocular hypertension. eLife. https://doi.org/10.7554/elife.104894
Vancouver
Rudzitis CN, Lakk M, Singh A, Redmon SN, Kirdajová D, Tseng YT, et al. TRPV4 activation by TGFβ2 enhances cellular contractility and drives ocular hypertension. eLife. 2025. doi:10.7554/elife.104894
BibTeX
@article{Rudzitis2025,
author = {Rudzitis, Christopher Nass and Lakk, Monika and Singh, Ayushi and Redmon, Sarah N and Kirdajová, Denisa and Tseng, Yun-Ting and De Ieso, Michael L and Stamer, W Daniel and Herberg, Samuel and Krizaj, David},
title = {TRPV4 activation by TGFβ2 enhances cellular contractility and drives ocular hypertension},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.104894}
}
EUVIMED